Combination studies of immune checkpoint inhibitors with cytotoxic chemotherapy or with molecularly targeted agents, such as inhibitors of the epidermal growth factor receptor or angiogenesis, are actively being conducted in different types of tumours. Here, EGFR is linked to neoplasm.